LIVE

GPCR

Structure Therapeutics Inc.

GPCR

NASDAQ·Healthcare·Biotechnology·Mkt cap $3.0B

$53.45

+2.55%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$15.80 - $94.90

P/E

-50.90

Fwd P/E

-27.18

Beta

-1.42

Div Yield

0.00%

Avg Vol

876.1K

Shares Out

Mkt Cap

$3.0B

Price action

Price chart

Up 155.0% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

No bull reasons captured for this rating yet.

Bear Case

1 risk

  • Low volatility (beta -1.4).

Growth

Revenue decline expected

Value

Deep value opportunity - significant discount to sector peers

Momentum

Stable

-2.5% over 3m

Quality

Loss-making

Below average quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 6, 2026

LATEST RECAP

Earnings recap unavailable for this period.

EPS surprise · last 4Q

Q1 26

-$1.05

Next: Aug 6, 2026

Revenue trend · last 1Q

Q1 26

$0

Margins · last 1Q

No margin history available.

Wall Street consensus

1 analyst · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

1

100%

Hold

0%

Sell

0%

Median Price Target

$101.00

+89.0% vs $53.45

Low $101.00
Median $101.00
High $101.00

Latest: HC Wainwright · Jun 11, 2026

1 analyst covering

vs Industry

How GPCR stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.

Related

Peers & themes

Peers

No peer data available.

Themes

No themes assigned.